Home / Transcripts / Arcutis Biotherapeutics, Inc. (ARQT) · October 28, 2025

Arcutis Biotherapeutics, Inc. (ARQT) Earnings Call Transcript

October 28, 2025

NASDAQ US Health Care Biotechnology earnings

Earnings Call Speaker Segments

Brian Scholkoff executive
#1

Thanks so much. Good morning to all of you, and I appreciate your presence as we go over the financial results and business update for our third quarter of 2025. For our extended Investor Day presentation, you can find the slides for today's call in the Investors section of the Arcutis website. With me on the call today are Frank Watanabe, who serves as President and CEO of Arcutis; Todd Edwards, our Chief Commercial Officer; Patrick Burnett, our Chief Medical Officer; and Latha Vairavan, our Chief Financial Officer. Later in the call, Douglas DiRuggiero will also join us — a certified physician assistant and doctor of medical science who has focused on dermatology for 25 years and serves as founding President of the Georgia Dermatology Physician Assistant Society. I want to remind all of you that during this call we will be making forward-looking statements. Such statements carry certain risks and uncertainties, and our actual results may differ; we encourage you to review all of the company's filings with the Securities and Exchange Commission, including descriptions of our business and risk factors; with that, let me turn it over to Frank for a brief introduction of today's call.

Todd Watanabe executive
#2

Thank you, Brian, and I appreciate everyone being here today and setting aside extra time on your schedules for what we think will be an engaging review of the solid groundwork of our company right now, plus a closer examination of how we intend to keep growing down the road. We'll kick off this call with a look at our commercial and financial performance for Q3. Todd and Latha will tell you shortly that we delivered one more excellent quarter, with powerful growth in net product revenue and ongoing, stable increases in prescriptions throughout every approved formulation and indication for ZORYVE. After that, we'll shift to the Investor Day presentation, where we'll dig deeply into the reasons we feel enthusiasm and confidence about what lies ahead for Arcutis and our distinctive capacity to tackle important unmet needs among patients dealing with immune-mediated dermatological diseases. This conversation about our corporate strategy comes at a fitting and relevant moment, since we are nearing cash flow positivity, which lets us fund our own business investments that will keep Arcutis growing. That enthusiasm rests first on the remarkable growth possibilities for ZORYVE, a groundbreaking topical treatment already transforming how chronic inflammatory skin diseases are managed, with an effect we expect will only grow larger in coming years. As you'll learn today, we see numerous chances to grow and broaden our ZORYVE business further, and we possess the abilities and means to seize those chances. We'll also share more specifics today regarding our work to build an exciting pipeline, beginning with ARQ-234, a novel biologic possessing best-in-class promise to fill a substantial unmet need in atopic dermatitis. Alongside the ZORYVE franchise, ARQ-234 and upcoming pipeline possibilities will let us carry forward our mission of championing meaningful innovation for patients affected by immune-mediated skin conditions and reinforce Arcutis' standing as one of the medical dermatology industry's most significant powerhouses. I'd also like to pause and thank the Arcutis team for their work and dedication to delivering better outcomes for patients who live with serious skin diseases. Their steadfast commitment forms the basis of everything we've achieved so far and will underpin the ambitious plans we outlined today. So, thank you once more for making time to be with us today. And now I'll hand the call over to Todd for our Q3 commercial update.

Todd Edwards executive
#3

Thanks, Frank, and good morning, all. Let's move to Slide 6. Like Frank mentioned, we kept up our strong revenue growth, powered by more patients and clinicians adopting the ZORYVE portfolio across every improved indication. During the third quarter, net product revenues came in at $99.2 million, which works out to 22% growth quarter over quarter and a 122% jump versus the same quarter of 2024. A big jump in revenue was driven by growing demand for ZORYVE, supported by increased prescription volumes for all products we offer; this easy-to-access launch represents a breakthrough in plaque psoriasis care, while the scalp and body products contributed significantly to the rise in demand, helping offset the typical seasonal challenges that occur in Q3. Improved gross-to-net rates for the quarter further boosted sequential sales growth, which came from reduced use of patient co-pay assistance as patients hit their yearly deductibles sooner than anticipated. As a result, we anticipate that the sequential gross-to-net gain will be smaller during Q4, consistent with what we've typically seen historically, and we expect just a slight further lift from co-pay program utilization. Turning to Slide 7. Just as in earlier quarters, our Q3 expansion was driven by continuing demand increases across every strength and indication. ZORYVE total prescriptions increased 13% compared with Q2 and 92% compared with Q3 2024. On a rolling 4-week average basis, weekly prescriptions reached an all-time high of over 17,000 scripts. Once the FDA cleared the reformulated 0.3% version for treating plaque psoriasis on the scalp and body back in May, and we launched it that June, the foam product really stood out — its revenue climbed over 25% versus the previous quarter. As you can see in the graph, total ZORYVE volume turned a corner following that launch, which really shows how big a difference this new indication has made. And importantly, throughout that stretch, ZORYVE cream 0.3% kept posting steady, growing volume too, which tells us demand is holding up for both formulations in plaque psoriasis. To sum up, the strong headway we carried into Q3 really shows how valuable ZORYVE is, how much more faith doctors and patients now place in our brand, and—even more significantly—the wider change in treatment that steroid conversion is bringing about. Later in today's presentation, we'll go deeper into what's driving this move away from topical clinical steroids, and I'm eager to tell you about the further steps we're taking to spark and speed up that transition soon. As we look toward Q4, we expect net sales to keep rising at a solid clip, fueled by more patients seeking treatment. At the same time, our gross-to-net rate should show only slight gains relative to Q3. Additional momentum will come from rolling out ZORYVE cream 0.05%, indicated for atopic dermatitis in children ages 2 to 5. I'll now hand things over to Latha, who will walk through the financial results for Q3.

Latha Vairavan executive
#4

Thanks, Todd. I'll pick up on Slide 8. Like Todd mentioned, our net product revenues in Q3 reached about $99.2 million — an increase of 122% compared with the third quarter of 2024, and up 22% from the second quarter of this year. Cost of sales for Q3 was $8.7 million, versus $5.5 million in Q3 2024, driven mostly by greater sales volume for ZORYVE. Third-quarter R&D expenses were $19.6 million, compared with $19.5 million in the same period of 2024. Our R&D spending held flat year over year, as clinical spending shifted from ARQ-255 toward pediatric reformulation studies. Going forward, we expect R&D spend to climb in 2026 as we continue advancing ZORYVE life cycle management and clinical development activities, and launch our Phase I trial of ARQ-234. SG&A expenses were $62.4 million in the third quarter of 2025, versus $58.8 million in last year's comparable period — a 6% rise linked to investments in our ongoing commercialization efforts for ZORYVE — but SG&A expenses fell about 10% from the second quarter of 2025, primarily because promotional and marketing spend was lower due to how expenditures were timed between quarters. Net income for the quarter was $7.4 million, compared with a net loss of $41.5 million in last year's same period and a loss of $15.9 million in the second quarter of 2025. This quarter's net profit came from a $17.7 million sequential increase in net sales together with a $5.4 million reduction in operating expense. While we don't expect net income to remain positive near term, the better operational leverage we demonstrated in the quarter — with ZORYVE's growing net sales contribution outpacing increases to our core expense base — speaks to the profit generation capacity of the ZORYVE franchise, which includes ZORYVE cream 0.15% for atopic dermatitis in children aged two to five years old. We previously said we expected to hit cash flow breakeven in 2026; however, continued momentum in ZORYVE net sales growth, combined with our expense discipline, has helped accelerate this important milestone, and we now expect to reach cash flow breakeven in the fourth quarter of 2025. Now to Slide 9. Our cash and marketable securities balance as of September 30, 2025, was $191 million, with cash burn from operations of $1.8 million for the period. We carry total debt of $108.5 million and have the option to draw another $100 million in whole or in part at our discussion through the middle of 2026, giving us flexibility to invest in continued expansion of our business. The success of the ZORYVE franchise and the economies of scale we are generating will allow us to invest in the business for sustained growth over the years ahead. I'll go into more detail on this when I discuss our capital allocation strategy later in today's presentation. With that, I'll hand the call back to Frank to kick off the Investor Day portion of today's call.

Todd Watanabe executive
#5

Thank you, Latha. Arcutis came into being back in 2016, and the reason we started it was a notable lack of innovation we perceived within the field of immunodermatology drug development. It's clear to us that most people with skin conditions were receiving legacy treatments that simply didn't work well enough, failed to go after particular disease mediators, and/or came with major problems around safety and how well they were tolerated. That's why we committed ourselves to finding, creating, and bringing to market molecules of the highest caliber that could serve dermatology's unmet needs by hitting immunological drivers of inflammatory conditions head-on. Toward that objective, we've stayed highly disciplined, intentional, and effective, consistently delivering on the potential of ARQ-151 and ARQ-154 — today called ZORYVE Cream and ZORYVE Foam — as a genuine pipeline-in-a-molecule prospect. With the major milestone of reaching cash flow breakeven drawing near, we've carefully been mapping out what comes next for Arcutis, a stage in which the very same concentration and commitment will be channeled into securing long-term expansion, achievement, and above all, lasting benefit for patients. Slide 11 lays out three pillars that form the strategic structure supporting our company's growth both near term and long term. To begin, we'll keep expanding our foundational ZORYVE business, cementing ZORYVE's role as the go-to therapy for grown-ups and kids who require continuous treatment options to manage psoriasis, cebroid dermatitis, and atopic dermatitis. A major piece of that growth pillar involves our ongoing work to answer rising demand for topical steroids alternatives that are safer and more targeted. That's a subject we'll devote considerable time to discussing today. This pillar also encompasses our push into primary care and pediatrics, plus in-line growth prospects like our recent rollouts in scalp and body psoriasis and pediatric atopic dermatitis, along with chances to generate additional data that strengthens ZORYVE's standing across the indications we currently have approved. Next, our intention is to broaden the ZORYVE franchise by way of strategic life cycle management. More precisely, we're assessing possible new indications marked by considerable unmet needs, where ZORYVE's distinctive profile could help patients. This search for new indications — a central element of how we approach clinical development — will be steered by a substantial collection of case reports from physicians who've prescribed ZORYVE for assorted other inflammatory dermatoses and witnessed promising efficacy signals. And last, we'll grow our pipeline by moving forward with additional novel medicines for patients, drawing on the top-tier clinical development and commercialization strengths we've built here at Arcutis. At the outset, our attention will go to ARQ-234 while simultaneously pursuing potentially promising outside innovation. As Slide 12 shows, we've structured today's agenda around the three strategic pillars I just described. We'll discuss sustainable growth drivers for the indications ZORYVE currently holds. During the presentation, Patrick will moderate a Q&A with imminent dermatology physician assistant Douglas DiRuggiero, giving us a clinician's view on how the treatment landscape is shifting. After that, we'll provide an overview of our expansion work, which includes exploring possible new indications for ZORYVE, starting with vitiligo and <<inaudible>>. And to close things out, regarding ZORYVE, we're going to share some perspective on what peak sales could look like. After that, we'll shift to talking about how we're building our pipeline, and that will cover a look at ARQ-234 along with the chance it has to fill a major unmet need in atopic dermatitis, plus a summary of how we assess business development possibilities. Then, to finish, we'll go over our approach to capital allocation and the balance sheet before we take questions. So with all that said, let's jump straight into the agenda. If you turn to Slide 13. It's been a little more than 3 years now since ZORYVE got its first FDA approval. In the time since, and as we showed once again today through our Q3 financial results, we've delivered meaningful and sustained growth across our 3 current indications by way of a steady drumbeat of new formulations, broader adoption within those syndications, and strong execution, which has driven consistent quarter-on-quarter prescription growth. Yet past those individual milestones, it matters to look at ZORYVE from a 30,000-foot view. From that vantage point, what we see is that no product has ever been as uniquely suited to treating immune-mediated inflammatory skin diseases as ZORYVE. As laid out on this slide, ZORYVE's unique profile, which really stands out among topical agents, falls into 3 key buckets. First, there's ZORYVE's pleotropic mechanism of action, combined with the variety of formulations it comes in. Patrick is going to go deeper into the MOA afterward. At a high level, though, PDE4 has demonstrated it may influence several inflammatory cytokines, lessen neuronal itch signaling, and enhance melanocyte activity. Second, ZORYVE delivers efficacy that is both fast and strong, spanning several dimensions across multiple dermatoses. You can likely picture how these first two buckets together give ZORYVE extraordinary potential usefulness over a broad range of inflammatory skin conditions — not just psoriasis, atopic dermatitis, and set derm, but possibly far past our 3 initial indications. The third point—and this really matters—is how ZORYVE performs on safety and tolerability, which allows it to be applied to any part of the body and for however long it's needed. When it comes to chronic use, its safety sets it apart from topical steroids, and that's a must-have quality when treating conditions that typically call for therapy lasting not merely one or 2 months, but spanning years and frequently an entire lifetime. This distinctive profile arrives at a moment when dermatology is undergoing a significant shift: corticosteroids, long the go-to standard of care for numerous inflammatory dermatoses, are now drawing greater scrutiny over their extended use, and a rising number of dermatology clinicians alongside patients are demanding long-term, targeted, nonsteroidal approaches to treatment. When it comes to skin conditions driven by immune-mediated inflammation, ZORYVE fits the bill — the right therapy, with the right characteristics, timed perfectly. Given how these elements come together, the room for ZORYVE <<inaudible>> to expand is enormous. At this point I'll hand things over to Todd, who will walk through ZORYVE's potential by looking at the market landscape.

Todd Edwards executive
#6

Appreciate that, Frank. On Slide 15 you can see a clear picture of just how large and how attainable the ZORYVE opportunity really is. Looking at the U.S., in the indications we have approval for right now—psoriasis, seborrheic dermatitis and atopic dermatitis—the number of diagnosed patients comes to roughly 30 million. Out of that total, around 19 million are already on a topical therapy, mostly topical corticosteroids written by doctors across essentially every specialty. Inside that subgroup, about 8 million are getting care in a dermatology specialty setting. That's the space where Arcutis has focused its commercialization push so far. So the serviceable obtainable market—patients already under dermatology care who already hold a topical prescription for their psoriasis, AD or seb derm—is sizable and very addressable. Which raises the key question: how much of that market can ZORYVE win back? With ZORYVE's differentiated clinical profile, the strong base built during the early commercialization phases, wide reimbursement coverage, a treatment landscape that keeps shifting, and the strategic steps we're taking to expand both the breadth and the depth of prescribing, we think lifting ZORYVE's share to 15% to 20% of topical steroid prescriptions—or possibly higher—is realistic and within reach. As we'll lay out in more detail today, there are strong reasons to believe ZORYVE is set up for meaningful, durable growth in the years to come. Now let's move to Slide 16. What grounds that conviction is what we can already watch happening in the market. On the left side of this slide, you'll see that across the past 6 quarters, branded non-steroidals have been steadily establishing a real foothold in the topical market. Over that stretch, non-steroidal topical volume—the middle bar—grew by more than 60%, whereas topical steroids, the yellow line, stayed basically flat. And within the non-steroidal category, ZORYVE is unmistakably the growth engine, with volume up almost 200% over that same period, as the topmost line shows. Corticosteroids continue to make up the overwhelming bulk of topical prescriptions today, which makes sense given they've served as the topical standard of care for chronic inflammatory skin conditions for more than 70 years. Even so, the treatment landscape is changing—both in the U.S. and around the world, demand keeps building for innovation in the topical space, innovation able to deliver better outcomes along with safety. Because of that, we're starting to see topical steroid share within the topical market erode. Importantly, this shift is still at an early stage, and a large base of topical steroid prescriptions remains available to convert. The chart in the middle shows that almost 70% of the 24 million annual prescriptions for psoriasis, AD and seb derm written by dermatology specialists are still for topical steroids. That works out to about 17 million topical steroid prescriptions every year—a substantial base that will keep driving ZORYVE's growth in the years ahead. And that figure doesn't even factor in the PCP NP opportunity yet. When you look at how much faster ZORYVE has grown than the wider nonsteroidal topical category, that has already turned into a sizable gain in share. On the right-hand side, you can see that close to 50% of all branded topical prescriptions now carry the ZORYVE name. Holding that number one spot puts ZORYVE in a very strong place to benefit from the continuing movement away from steroids. Patrick is going to take a closer look at where things stand with the conversion from topical steroids and what is pushing that change in practice. Patrick?

Patrick Burnett executive
#7

Thanks, Todd, and hello everybody. We'd like to take a few minutes to go deeper on the momentum surrounding steroid conversion. First, since it points to a pivotal paradigm change in how immune-mediated inflammatory skin diseases get treated; and second, since it gives us an important data point supporting the obtainable market thesis Todd laid out. So what precisely is fueling this conversion? And why should it matter? The earliest successful application of corticosteroids for chronic inflammatory skin diseases was documented in 1952; across more than 70 years, we've witnessed extraordinary scientific and medical breakthroughs spanning numerous therapeutic areas and treatment modalities; yet topical steroids have stayed a cornerstone in managing conditions such as atopic dermatitis and psoriasis. The arrival of biologics marked a significant step forward in treating immune-mediated inflammatory skin conditions. Yet, even though these novel therapeutics have helped the subset of patients whose disease is more severe. For the vast majority of patients, topicals still overwhelmingly serve as first-line therapy. And patients on biologics frequently keep depending on adjunctive topical treatments to handle residual disease and breakthrough flares. Health care providers, professional societies and patients increasingly recognize that long-term topical steroid use may be tied to serious adverse effects, both local and systemic, and this has set the stage for louder demands to restrict long-term topical corticosteroid use and welcome innovation in the topical modality. To help you understand what's driving this widespread, vocal global alarm about topical corticosteroids, I'd like to put the issue in context. For that purpose, we've borrowed a slide from a recent review article written by Douglas DiRuggiero, who will join me later in this program for a conversation. Slide 17, on its left side, displays the roster of typical localized side effects brought on by long-term steroid therapy. The majority of these were thoroughly documented as far back as the 60s, and they encompass harm to the skin barrier, atrophic alterations such as stria or stretch marks, the development of cataracts, and slowed wound healing. Crucially, the adverse effects tied to topical corticosteroids aren't confined to localized ones. Turning to the right side of this slide, you'll find enumerated various systemic consequences — wide-ranging and significant ones — such as hormonal disruption affecting reproduction, inhibited growth, weakened bones and fractures, diabetes, plus eye-related issues like clouded lenses and elevated eye pressure. Only relatively recently, as several papers on topical treatments have come out, has the obvious link between accumulated exposure to steroids applied to the skin and a higher likelihood of broken bones and diabetes been completely recognized. These findings confirm the mounting worry that using topical steroids over an extended period carries dangers quite similar to the familiar side effects that have turned systemic steroids into a last-resort option for the majority of inflammatory conditions. Even though the chance of experiencing these side effects goes up when a steroid is stronger or applied for a longer time, reports have still surfaced involving weaker options or brief usage. Additionally, infants and children may be at the highest risk, because their skin issues tend to affect a bigger share of their total body area than is typical for adults, and because their immature skin barrier allows more to pass through. And finally, groups of patients facing even greater danger include those applying topical corticosteroids to the face or genital regions, since skin in those central areas is not just more susceptible to localized negative reactions, but comes with higher permeability and more drug absorption, particularly among individuals with atopic dermatitis or separate dermatitis, because of the inherent barrier malfunction in these conditions. Doctors are more and more frequently recognizing that a lot of patients aren't just exposed to topical steroids, but could also be taking other steroid therapies such as inhaled, intranasal, or even oral steroids, and this overall accumulated steroid exposure sharply raises the danger of negative steroid consequences. Considering everything we've discussed, it's clear why we're so committed to addressing these expanding problems and applying scientific advances to bring patients more accurate treatment choices that are both effective and safe. On Slide 18, you'll see that in August of this year, two leading U.S. dermatology professional groups — the Society of Dermatology Physician Assistance, known as the SDPA, and the Society of Dermatology Nurse Practitioners, or SDNP — issued statements recognizing the mounting evidence behind these potential adverse effects and the importance of turning to sophisticated topical targeted treatments that reduce reliance on continuous topical steroid use. What we have here is the latest item in a growing list of high-profile calls to limit how topical steroids are used, and that's because of the harms they can cause. Those calling for restrictions include regulators in Canada, the United Kingdom, and India, along with other professional groups such as the International Eczema Council, British Dermatological Nursing Group, British Association of Dermatologists, and the American Academy of Family Physicians. Patient advocacy groups like the National Eczema Society and National Eczema Association are part of this too, as are several physician expert consensus panel recommendations that came out recently. So it's clear this isn't simply one region speaking up on its own — it's a wave happening across the globe. Within the United States, the recent recognition from the SDPA and the SDNP carries particular weight given how vital physician assistants and nurse practitioners are when it comes to selecting treatments for individuals living with chronic inflammatory skin conditions. Moving on, we'd like to present a discussion I held not long ago with Douglas DiRuggiero regarding how the topical treatment options for immune-mediated dermatosis are evolving. Douglas DiRuggiero holds credentials as a certified physician assistant and a doctor of Medical Science, and he has devoted the last 25 years to dermatology. He is part of the skin cancer and cosmetic dermatology center, which is known nationwide for delivering sophisticated dermatologic care to both adults and children across Northwest Georgia and Southeast Tennessee. Douglas also serves as the Founding President of the Georgia Dermatology of Physicians Assistance Society, and the National Psoriasis Foundation just gave him a national Honoree designation—no physician assistant had ever earned that recognition before. On the subject of possible negative consequences tied to using topical corticosteroids over an extended period, he has produced a great deal of writing and given many talks. In my view, the best entry point for this conversation with Douglas is to highlight the role that physician assistants and nurse practitioners play in dermatology. A growing portion of direct skin care—including the writing of prescriptions—now comes from NPs and PAs, and part of the reason for that expansion is greater demand for dermatologic treatment, given that dermatologists cover medical dermatology alongside surgical procedures and cosmetic services. By stepping into essential gaps, these NP and PA clinicians help guarantee that people dealing with skin conditions can obtain the important, top-quality care they require. So, Douglas, I'd like to express my appreciation for you being here with me and for your willingness to join us and offer some of the perspectives you've gained across nearly 30 years in practice. In particular, I'm eager to speak with you in light of the paper you released regarding how topical corticosteroids act systemically. That struck me as a truly outstanding review, and I took away a great deal from it. I figured it would be wonderful to have you on to share the thinking behind it.

Patrick Burnett executive
#8

Moving on to Slide 20, I'd like to revisit some analysis we presented back in 2023 regarding historical analogs, where more recent categories of medications upended long-standing treatment models, overturning deeply rooted generic standards of care. These involve 4 separate conditions that each had well-entrenched generic standards of care which got disrupted by innovative treatments that were safer, more effective, or more convenient, spanning the anticoagulation, depression, GERD and schizophrenia markets; it took somewhere between 5 and 10 years before those newer innovative therapies managed to seize 50% of the serviceable obtainable market. It has been a little over 3 years since we got our first indication in psoriasis, just under 2 years for seb derm, and merely 15 months since our AD launch. We are only beginning and anticipate the ongoing transformation of the treatment paradigm for these conditions. Picture the growth potential if the topical anti-inflammatory market were to convert merely half as much as those other markets. Then on Slide 21, we call attention to important elements of the topical steroid profile that fueled their extensive uptake in dermatology, so we can grasp what profile a nonsteroidal option must attain to compete successfully. It essentially boils down to 2 essential traits. First, similar to topical corticosteroids, the medication must be effective at clearing both inflammation and itch, and it must act rapidly. Second, topical steroids are effective across numerous of the most prevalent skin conditions such as atopic dermatitis, psoriasis and cebra dermatitis, along with many of the rarer conditions, where there might not be any FDA-approved treatment at present. So akin to topical corticosteroids, the medication likewise must be effective across a broad range of indications; this differs from what is expected of a systemic treatment, where a more targeted approach is preferred. Now think about which traits a medication would require to go past merely competing with topical steroids, instead replacing them as a better therapy for chronic inflammatory dermatosis. Individuals suffering from these chronic conditions urgently require topical medications that can be safely used across a prolonged time frame to prevent flare ups, while lowering the risks and adverse effects tied to extended topical corticosteroid use; furthermore, the treatment must be safe and easy to apply to various regions of the body, including difficult-to-treat regions such as the scalp and sensitive regions such as the face and growing, all of which inflammatory dermatosis can impact. I will go over ZORYVE's MOA thoroughly a bit later during my presentation. Much like steroids, ZORYVE exerts a broad influence on numerous biological processes involved in immune-mediated inflammatory skin conditions. This sets ZORYVE apart from biologics that focus on highly specific pathways and other branded topicals that operate through a narrower range of mechanisms; and indeed, as Frank noted earlier, ZORYVE, being a potent inhibitor of PDI, delivers even wider effects compared to steroids, directly affecting neuronal itch signaling and melanocyte function alongside decreasing inflammation. We have built up a considerable collection of clinical evidence backing our 6 FDA approvals, which show ZORYVE's safety and efficacy profile when used long term across a range of disease states and basically every region of the body. As you can observe, ZORYVE satisfies every criterion for the ideal profile — not just to compete against topical steroids, but potentially to take their place — which helps clarify why ZORYVE keeps quickly capturing share from topical corticosteroids. I'll hand things over now to Todd to talk about our continuing commercial work in the primary care physician and pediatric specialties.

Todd Edwards executive
#9

Thanks, Patrick. I'm on Slide 22 now. Widening the range of prescribers past dermatology is going to be a major force behind ZORYVE's ongoing expansion. At the start, we concentrated on dermatology practices, since that gave us a rollout that was efficient in both time and resources — the fairly small group of dermatology prescribers writes about 50% of all topical scripts for inflammatory dermatosis. We keep making solid progress with dermatology practitioners, but we've also stepped up our work to grow reutilization in primary care and pediatric settings, where more than 13 million topical prescriptions get written each year for the indications we currently have. Our partnership with <<inaudible>> is how these initiatives are being pushed forward. In primary care and pediatrics, a lot of providers have had only limited exposure to topical nonrate treatments, so they tend to default to prescribing steroids. The <<inaudible>> team is using a targeted, high-frequency approach to spark initial trial and, in the end, adoption of ZORYVE with these providers and the patients they treat. As our thyroid conversion movement keeps building momentum and visibility, we believe it will have a growing influence on how prescribing happens in these settings. The total universe of primary care and pediatric providers is huge, but our joint commercial strategy with <<inaudible>> is both strategic and extremely focused. The pie charts on the right of this slide show that out of the more than 0.5 million total PCPs and pediatricians in the U.S., the top 30,000 prescribers represented roughly 5%, or 4 million prescriptions — close to 1/3 of all prescriptions in these segments. Those high-volume prescribers are where we're concentrating, and they give us confidence that this strategy can officially drive growth. Our activation in primary care and pediatrics is still at an early stage. And we're committed to pushing ZORYVE's penetration in these settings so that this large pool of patients gets an alternative treatment option to topical steroids. I'll hand the call back to Patrick now, who will go deeper into the opportunities to keep growing ZORYVE, psoriasis setter, and AD through targeted clinical activities. Patrick?

Patrick Burnett executive
#10

Alright, thanks, Todd. We're going to shift focus now to the ways ZORYVE can grow through broadening the indications we already have, making sure we're able to get ZORYVE to the widest possible group of psoriasis, seborrheic dermatitis, and atopic dermatitis patients who stand to gain from this drug's distinctive characteristics — that continues to be a top priority for us. Our label expansion programs, both the ones being planned and those already running, aimed at helping pediatric plaque psoriasis patients along with pediatric and infant atopic dermatitis sufferers, sit at the heart of pushing this objective forward, as we've laid out on Slide 23. For pediatric and infant atopic dermatitis patients, there's an urgent demand for novel options beyond topical corticosteroids. In contrast to other inflammatory skin conditions, atopic dermatitis frequently shows up at very young ages. Close to 10 million kids across the U.S. deal with atopic dermatitis, and about 60% start showing symptoms within their first year of life. Atopic dermatitis brings particular difficulties for these younger age groups — not just because their skin tends to be more sensitive, but also because the condition typically affects a larger share of their total body surface area than it does for adolescents and adults. Parents of these young patients are especially worried about possible adverse effects from topical steroids. Those worries span everything from how long-term steroid use might affect a child's growth and bone development to more immediate issues such as getting the product in the child's face or having it come into contact with the eyes and mouth, which can be tough to manage. Considering how large this patient population is and how strongly people want safer, better-tolerated treatments, we've been systematically working toward expanding ZORYVE's label to cover younger atopic dermatitis patients. Earlier this month, we won approval for our supplemental NDA covering ZORYVE Cream 0.05% to treat atopic dermatitis in children between 2 and 5 years old — a group of roughly 1.8 million patients. Launch activities for commercialization have begun, and we're thrilled to deliver this important new — this new treatment choice to clinicians and, above all, to pediatric patients and the people who care for them; at the same time, we're working on developing ZORYVE Cream 0.05% for atopic dermatitis in even younger AD patients, from 3 months to 24 months of age. Enrollment in our integument infant trial covering that age range has moved quickly and gone beyond typical enrollment rates and what we had expected, which confirms there's substantial interest in nonsteroidal treatment choices. Beyond atopic dermatitis, we're also working toward a label expansion for treating pediatric plaque psoriasis patients. Even though this group is smaller than the pediatric atopic dermatitis one, there's still a pressing need for improved therapeutic options that we continually strive to address. On September 2, we shared that we're filing a supplemental NDA for ZORYVE cream 0.3% to broaden its indication to treating plaque psoriasis in kids ages 2 to 5. Assuming it gets the green light, ZORYVE cream is set to become the first and only topical PDE4 inhibitor approved for plaque psoriasis in kids as young as 2 years old, giving patients and caregivers a meaningful option beyond topical steroids and vitamin D analogs. ZORYVE Cream's formulation is distinctive in being effective, safe, and well tolerated across all body areas, even sensitive ones like intertriginous skin, where plaque psoriasis frequently shows up in children. For kids under 6 with plaque psoriasis, FDA-approved treatment choices are extremely scarce. This clinical data package is something we take great pride in, and in having assembled it to back this sNDA, and we await the FDA's ruling. Moving on, Slide 24 covers incremental data generation opportunities our clinical team is chasing to further strengthen ZORYVE's standing within the indications we currently have approved. What these efforts are worth is generating clinical data that can be cited with health care providers, reinforcing the robust and diverse effects of ZORYVE in plaque psoriasis, atopic dermatitis, and seborrheic dermatitis. These efforts are meant to strengthen the label of current indications by cementing ZORYVE's place among health care providers as a foundational pick among the various options for managing these dermatoses. Notable examples in this effort include palmoplantar psoriasis, nail psoriasis, and cicatricial or scarring alopecia, when it appears alongside seborrheic dermatitis. Much like nail psoriasis, palmoplantar psoriasis is a manifestation of plaque psoriasis in a specific body area, and both conditions fall within our indicated patient treatment population for ZORYVE. Palmar-plantar and nail psoriasis pose unique clinical challenges and have historically responded less well to standard of care topical therapies and even to available systemic therapies. That said, we've gotten signals from the field, through both formal case reports and informal dialogue with HCPs, that ZORYVE makes a real impact in these challenging locations. Our aim is to validate that impact through generation of data that could be shared with the HCPs we engage with. We believe that showing efficacy in these difficult-to-treat patients will lead practitioners to default toward using ZORYVE as their preferred topical therapy for their psoriasis patients. Now, at present, scarring alopecia, a group of related conditions, leading to irreversible hair loss, has no FDA-approved treatment. Clinicians tell us that many patients with scarring alopecia also present with seborrheic dermatitis, and there's a belief that these 2 conditions may be linked. This comorbidity is particularly well documented in publications that demonstrate that over half of patients with central centrifugal cicatricial alopecia, also known as CCCA, 1 form of scarring alopecia, also have seborrheic dermatitis, and researchers have proposed that aggressive management of their receptor may reduce the disease incidence, reduce its severity and the psychological burden in patients with CCCA. Again, if the clinical data that we produce validates a unique efficacy profile for patients with seborrheic dermatitis and scarring alopecia, we believe that it will drive preferential usage of ZORYVE versus other sebderm treatments. With this incremental data generation possibility, you only need small data sets and a modest spend, yet it still pushes prescription depth within these underserved subpopulations. Because of that, the approach is extremely efficient with resources. Such work will further inform clinical treatment choices; moving now to Slide 25, you're able to view chosen images taken from case reports we have obtained involving both palmoplantar psoriasis and nail psoriasis. Although the meaningful effect of ZORYVE shown in those pictures must be validated via our own clinical evaluation, it is simple to understand why the field is sending us such enthusiastic feedback regarding what might be possible for these patient subsets. So I'll hand things back to Todd so he can put into context how the pieces of our strategy reviewed up to this point to grow and expand ZORYVE will affect our market opportunity.

Todd Edwards executive
#11

Thanks, Patrick. If you’ll move with me to Slide 26. Earlier today, we walked through the main forces behind ZORYVE’s expansion within the indications we already serve: ongoing switching away from steroids, growth into the primary care and pediatric specialty labels, and the creation of intraretinal data covering particular patient subgroups. Those growth levers are set to widen our market opportunity in two separate ways. The first is that our addressable market will grow to 17 million patients, since we keep extending our reach past dermatology and thereby double the number of patients across the specialties in which we already sell commercially. The second is that we anticipate further gains in ZORYVE’s portion of all topical prescriptions. To give a sense of the opportunity simply among the subset of health care providers we target in dermatology, primary care, and pediatrics: each single percentage point of additional share in topical steroid prescriptions works out to roughly $150 million in yearly net sales. As we increase that share from where it stands now toward the 15% to 20% range we regard as attainable, ZORYVE on its own will become a blockbuster franchise in these 3 indications. Patrick will now go over how we intend to bring ZORYVE into additional markets.

Patrick Burnett executive
#12

Thanks, Todd. So now we're moving from the phase of growing our core ZORYVE business within the indications we already have approved, into the phase of expanding the ZORYVE franchise by looking into possible new indications. From the very beginning, going after new patient groups who might get benefit from ZORYVE has been a main pillar of how we approach clinical development. You can see that in the 5 expansions we've obtained spanning plaque psoriasis, seborrheic dermatitis and atopic dermatitis, after we first got approval for plaque psoriasis back in 2022. Our view is that there are other skin diseases that could respond to it, and more patients who could gain from ZORYVE. That view rests not just on what we know about ZORYVE's broadly applicable anti-inflammatory and antipruritic properties, along with its possible effect on stimulating melanocytes, but also on the direct, ongoing input we get from health care providers out in the field regarding their real-world ZORYVE experiences. To help you grasp how and why ZORYVE could have potential across such a wide range of skin diseases, let me spend a moment reorienting you to ZORYVE's MOA, its mechanism of action. In particular, its pleotropic nature. ZORYVE works by inhibiting phosphodiesterase 4, or PDE4. That's an enzyme with a key role in inflammation. Through raising levels of cyclic adenosine monophosphate, or cyclic AMP, an intracellular messenger in immune cells, PDE4 regulates inflammation. That rise in cyclic AMP then affects multiple biological processes tied to immune-mediated inflammatory skin conditions. To be specific, it brings down the expression of several key pro-inflammatory cytokines, among them interferon gamma, type 1 interferon alpha, TNF alpha, IL-4, IL-6, IL-17 and IL-23, which covers signaling through the TH1, TH2 and TH17 immune-mediated responses. A key role in sensory neuron activation is also played by PDE4. So blocking PDE4 probably directly mediates the itch sensation. On top of that, PDE4 inhibition normalizes keratinocyte activation and differentiation, which can result in lessening the epidermal barrier dysfunction seen in many inflammatory dermatosis. And last, it boosts melanocyte proliferation, melanocyte gene and protein expression, and shields melanocytes from apoptosis. How many mechanisms and pathways ZORYVE touches is in sharp contrast with the very limited, specific pathways that biologics for inflammatory dermatosis go after. Usually these targeted therapies affect one or just a handful of cytokines in the inflammatory cascade. Because of that narrow focus, these therapeutics can't be applied widely across dermatosis the way ZORYVE can. Take inhibiting IL-23 — it's great for treating psoriasis, yet it does nothing for atopic dermatitis or many other inflammatory dermatoses. Another potentially important differentiator between ZORYVE and other topical anti-inflammatory treatments may be its unique pleiotropic MOA. Crucially, ZORYVE hits this broad set of inflammatory pathways in inflammatory dermatosis while not causing systemic immune suppression, and so it sidesteps the deleterious effects that often come when a company broadly knocks down the immune system with systemic therapeutics. It also sidesteps a lot of the harmful consequences that come with using steroids on the skin, among them local skin reactions and systemic issues like suppression of the HPA axis, problems regulating glycemic levels, osteoporosis along with osteoporotic fractures, and ophthalmological AEs. Because ZORYVE has a comprehensive MOA and comes with a safety and tolerability profile that is very favorable, we are in a unique position to apply it broadly across an exceptionally wide variety of indications and patient populations. So far, this has covered plaque psoriasis, AD, and seborrheic dermatitis. It might additionally let us address conditions in which topical corticosteroids provide no benefit or are not utilized, for example hidradenitis separative and Haley Haley disease, or conditions where their efficacy is low and their use is restricted because of topical adverse events, which is what happens with vitiligo and cutaneous lupus. Now I want to discuss how ZORYVE's pleatropic MOA translates broadly in the clinical setting. As part of what we are obligated to do as a manufacturer of ZORYVE, our medical team keeps track of this clinical feedback. So far, as Slide 29 shows, we have found more than 40 published case reports from clinicians who used ZORYVE across a multitude of other inflammatory dermatosis and who observed encouraging signs of efficacy; these clinicians have found a safe, tolerable, versatile, and effective profile for ZORYVE among their psoriasis, AD, and seb derm patients who independently opted to explore novel applications of the therapy. What these clinicians have done provides valuable initial signals that our life cycle management process then builds upon. This chase for potential new indications lines up with how we originally understood ZORYVE's pipeline in a molecule opportunity, and our method for assessing these potential opportunities is stepwise and resource efficient, as the simple graphic on the right-hand side of this slide outlines. When indications of interest emerge, we will run exploratory Phase II proof-of-concept studies where appropriate to assess the degree of response and to understand potential safety and efficacy. Drawing on what these initial studies show, our analysis of the unmet need and the addressable patient populations for a given disease, plus discussions with regulatory agencies, will then determine whether moving ahead with a registrational trial is a prudent use of capital given the anticipated return on investment. Importantly, the investment we intend to make in pursuit of these additional potential indications entails a very efficient deployment of capital. For the FDA to approve ZORYVE for these additional patient populations, we would instantly achieve operating leverage on our existing sales force, supply chain, and operational foundation that is already in place to serve patients for our core ZORYVE business. During our Q2 earnings call, we went over how we'd chosen 2 first exploratory indications—vitiligo along with hidradenitis suppurativa, or HS—and we're now conducting proof-of-concept Phase IIa trials, plus we expect to kick off a number of additional Phase II studies during 2026. If you look at Slide 30, there are selected images drawn from compelling case reports that came to us involving patients with merely a few of the skin conditions shown on the slide before, namely lupus, Hailey-Hailey disease, and neurodermatitis affecting the scalp. Let me now shift to the unmet needs and the possible opportunity that exists in vitiligo and hidradenitis suppurativa. These first 2 possible indications we are investigating came from case reports in the field, beginning with vitiligo on Slide 31. An immune-mediated inflammatory condition, this immune-mediated inflammation disorder is marked by loss of pigment, or melanin, and patches on the skin, producing white or lightly colored areas. With vitiligo, the immune system wrongly attacks and eliminates melanocytes—the cells that handle pigment production and skin pigmentation. Vitiligo comes in several types depending on how depigmented patches are patterned and distributed, and nonsegmental, or generalized, is the type seen most often. No cure exists for vitiligo. Topical corticosteroids have long been standard of care, yet their efficacy is limited, and side effects from extended use can pose a challenge. Opzelura won FDA approval in 2022 to treat nonsegmental vitiligo, and close to half of Opzelura's present usage goes to this indication. You'll remember that within the multi-pathway MLA, PV4 inhibition via roflumilast, the active ingredient inside ZORYVE, not only regulates inflammation—the root cause behind vitiligo—but additionally boosts melanocyte proliferation, melanocyte gene and protein expression, and shields melanocytes from hepatosis.

Patrick Burnett executive
#13

Consistent with the MOA, we have taken great encouragement from numerous case reports provided by clinicians who explored vitiligo as a new use for ZORYVE and demonstrated positive outcomes when treating vitiligo using ZORYVE 0.3% cream administered once daily. In the Phase II proof-of-concept study that is currently underway, our plan is to enroll 20 patients; when deciding whether to move the program forward into a Phase III trial, we will take into account the clinical profile observed in that Phase II trial, together with data seen in the field. Also considered will be a stringent assessment of the commercial opportunity we would anticipate given clinical results, and how that stacks up against findings from our other life cycle management trials. When it comes to vitiligo specifically, a clinical result we might view as compelling could resemble Opzelura-like efficacy combined with faster onset of symptom relief and a dosing schedule that is more convenient. Naturally, we require feedback from regulatory agencies to establish what a suitable Phase III trial design would be, yet we expect the size and cost of a registrational program to resemble those we have run for ZORYVE's approved indications. That said, treatment duration — reflecting how rapidly the disease responds to therapy — might affect development cost; we think certain elements of ZORYVE's profile would position it as an attractive therapeutic choice compared with currently available treatments, for instance once-daily dosing and the fact that ZORYVE carries no contraindication with therapeutic biologics or immunosuppressants. Let's now examine ZORYVE's potential opportunity in hidradenitis suppurativa, or HS, on Slide 32. HS is a chronic, recurrent, inflammatory skin condition that produces painful nodules, abscesses and tunnels. At present, diagnosis and treatment rates stay low because treatment options are limited. HS entails dysregulation of several key immune pathways that ZORYVE's MOA targets, among them TNF alpha, IL-6, IL-17 and 23, and interferon gamma. Topical and oral antibiotics serve as common first-line therapies for mild HS, yet they deliver insufficient relief, with a high proportion of patients either not improving or relapsing. Past antibiotics, choices are confined to systemic therapeutics, which include corticosteroids, costly biologics or difficult procedure-based surgical therapies. It is also worth noting that extensive off-label experience exists with a <<inaudible>>, an oral PDE4 inhibitor, in treating HS. In short, this is a painful, very difficult to manage chronic disease, with many patients not served by the therapeutic approaches currently available. We believe an effective nonantibiotic topical anti-inflammatory would represent an important therapeutic option within the treatment paradigm for these underserved patients, especially at the milder end of the severity spectrum. In the Phase II proof-of-concept study that is ongoing, we plan to enroll 20 patients, assess efficacy, tolerability and the rate at which relief onset occurs with ZORYVE; how we approach the decision on whether to advance the program to a Phase III trial will match the approach taken in vitiligo. We will assess the strength of clinical data and the implied commercial opportunity, and weigh that against other opportunities across our life cycle management program. There's also a strong case on the addressable patient side, with prevalence running between 3 million and 3.5 million. Sadly, among those patients the rate of diagnosis sits at under 15%, which is low, and that's partly because there's a shortage of effective therapeutic interventions that actually exist. Looking ahead over the next 10 years, industry forecasts call for significant growth in the diagnosed and treated HS population, grounded in the expectation that, as happened earlier with psoriasis and atopic dermatitis, fresh therapeutic choices ought to fuel more disease awareness, more diagnosis, and wider treatment. At present, work on new therapeutics for HS is clustered mostly around the more severe stages of the disease and is made up chiefly of systemic treatments; our view is that ZORYVE, should it show activity in the clinic, might serve as a significant topical therapy for mild to moderate disease, complementing the systemic treatments both already approved and still in development. Moving to Slide 33, you'll find strong illustrations of how ZORYVE affects patients who have vitiligo and HS. Over on the left, 2 vitiligo patients show noticeable repigmentation across spans of 7 and 5 months. Over on the right, you can observe meaningful clearance of hidradenitis super teva lesions within only a 30-day span, along with less inflammation and a return of pigment to normal. These chosen cases serve to illustrate the promising signals coming to us from clinicians, and why we're eager to confirm further, in a controlled clinical setting, what the effects are for these conditions. I'll hand things over now to Todd.

Todd Edwards executive
#14

Appreciate that, Patrick. Moving to Slide 34 now. When we think about what's ahead and the chance to grow the ZORYVE portfolio further, it's worth stressing once more the way extra indications can compete and shape how prescribers behave — something we've pointed out before. What we've seen is that doctors writing ZORYVE for more than one condition end up producing a notably larger overall volume of prescriptions, since they appreciate both the wide-ranging disease management advantages and the outstanding tolerability ZORYVE delivers for their patients. We anticipate that the possible arrival of further label expansions, along with communications, could intensify this pattern even more, acting as a major force behind prescription-writing depth among HCPs and underpinning continued volume growth for ZORYVE going forward; on to Slide 35 now. The significant work the clinical team at Arcutis is carrying out could widen the patient population able to gain from ZORYVE. If those clinical efforts turn out successful and we obtain regulatory approval. We would then see growth in our total serviceable and <<inaudible>> market, which fuels greater commercial opportunity for the franchise. Let me pass it back to Frank now. Thanks.

Todd Watanabe executive
#15

Before we change direction and dedicate time to discussing how we plan to build out our clinical pipeline, I'd like to briefly bring together every foundational piece behind the extraordinary opportunity ZORYVE presents to us. We're going after an enormous treated patient population, with over 17 million patients making up the addressable market. With ZORYVE, we have a drug possessing all the key attributes that made TCS a dermatology mainstay for decades, above all its level of efficacy across numerous inflammatory dermatoses. Yet what ZORYVE offers that TCS cannot is a profile that is safe and tolerable for extended use in these chronic conditions, the capacity for application to any part of the body, and mechanistic aspects involving neuronal signaling and melanocytes that fall outside what TCS provides. On top of that, we're launching this therapy at a moment of dramatic change in the way clinicians and patients view appropriate topical steroid use for managing these conditions. This combination of forces leaves us extremely confident about ZORYVE's prospects for meaningful, sustainable growth. When we put it all together, we envision a future in which our portion of the topical steroid market climbs from the roughly 3% level we hold today to 15% to 20% or beyond. That share gain won't occur overnight. As was covered earlier, a therapeutic conversion of this kind takes time to bring about. Still, for the reasons we've discussed, we feel confident we're on track to reach that degree of penetration. Furthermore, as we near this inflection point where our core business starts generating positive cash flows, we'll have extra resources available to put back into ZORYVE and spur that share growth. Past the near-term opportunity from the indications already approved, ZORYVE's peak potential will also come from broadening our indicated patient population via life cycle management, which Patrick just took us through. Taking both of these dynamics into account, we project peak market potential for the ZORYVE portfolio at somewhere between $2.6 billion and $3.5 billion. Let's turn now to the last pillar of our corporate strategy: building for the future with a pipeline of innovative medicines. As I mentioned at the beginning of today's presentation, our mission is to deliver meaningful innovation to patients affected by immune-mediated inflammatory skin diseases. As we move toward sustained profitability, we're well positioned to broaden our focus toward building and advancing an innovative pipeline aimed at additional unmet needs consistent with that mission. These pipeline efforts encompass launching the Phase I clinical study of ARQ-234 in atopic dermatitis along with continuing work to assess externally sourced assets. Patrick will now return to take us through both elements of our innovative pipeline strategy.

Patrick Burnett executive
#16

Thanks, Frank. Moving to Slide 39 now. During our previous call, we pointed out a key milestone: in Q2 we submitted an IND for ARQ-234, a first-of-its-kind systemic therapy aimed at moderate to severe atopic dermatitis. With preparations underway to launch our clinical trial for ARQ-234, we'd like to take some time today to walk through the untapped potential in the atopic dermatitis space and the significant role this molecule could potentially fill. ARQ-234 works as an agonist of the CD200R immune checkpoint, a target that has been clinically validated and is located on activated immune cells. Oncology was reshaped by immune checkpoint inhibition, which altered treatment approaches for a great number of cancers. When checkpoints such as PD-1 and PD-L1 are blocked, the patient's own immune response is put to work, and that shift fundamentally rewrote the paradigm for how oncologists think about and choose to treat many types of cancer. With the CD200R mechanism as our target, we intend to deploy immune checkpoints in the opposite direction — activating the checkpoint instead of suppressing it — allowing immune system homeostasis to be restored in those patients whose immune systems are overactive in a way that produces autoimmune disease. Controlling atopic dermatitis, as well as other autoimmune conditions, may be achievable through this form of checkpoint agonism, which represents a novel and possibly powerful approach. Even though there’s reason to believe this mechanism could matter for many autoimmune and inflammatory conditions, our first evaluation will focus on atopic dermatitis, since that’s where clinical validation is most solid. AD remains an appealing area for creating new biologics, and there are two main reasons why. First, relative to other inflammatory skin conditions like plaque psoriasis, biologic use is still at an early stage. Roughly 25% of patients who qualify receive systemic therapies for plaque psoriasis, while in AD only 10% of eligible patients are treated with systemic therapy. Evidence suggests that when additional biologics enter this space, biologic use across the market should grow in step—much like what occurred with plaque psoriasis, a market that went from 2014 to 2024 expanding nearly 300%, reaching about $23 billion, once therapies targeting IL-23 and IL-17 became available. We anticipate similar expansion for AD in the coming years, with forecasts indicating a CAGR above 10% through the decade's close, which would drive more than 80% growth in U.S. sales for this indication. Relatedly, and second, doctors want biologic choices other than dupilumab, presently a top approved biologic for AD. That said, there's still a major gap to fill. From our discussions with clinicians, one message comes through loud and clear: they want new mechanisms for tackling atopic dermatitis in patients who don't respond well enough to dupilumab, a drug that works by blocking the inflammatory mediators IL-4 and IL-13. CD200R agonism is a distinct mechanism of action — one that complements and sets itself apart from other AD therapies aimed at IL-4, IL-13, or OX40 and OX40 ligand. On multiple measures, ARQ-234 could stand apart, among them efficacy, responder sets, how long responses last, how often it's dosed, and safety. As for what other biopharma companies pursuing the CD200R pathway have demonstrated in clinical development, the durability of response after the final dose, once treatment stops, appears encouraging. A broader restoration of immune homeostasis through this checkpoint mechanism, rather than going after particular cytokines or other pieces of the larger immune cascade, might offer a distinct advantage. The CD200R field is still fairly young, but I'd like to point out several features of our candidate that we think could set our program apart from the other CD200R programs that are underway or were tried before. ARQ-234 binds a different site — one we view as optimized — at the native location. As a fusion protein, it also binds with greater affinity than a monoclonal antibody would. On top of that, we saw a longer half-life for the molecule, which comes from selective mutations built into the fusion protein. Given these unique characteristics, ARQ-234 has the potential to emerge as a leading program in its class, clearly distinguishing itself from other systemic treatment options available in the AD market. In our assessment, that market will offer abundant attractive opportunities for new therapies entering over the next several years. Additionally, following a recent disappointment that affected development efforts targeting other MOAs in AD, such as OX40, the present time is ideal for us to advance this program into clinical development. When we consider portfolio strategy, we likewise find compelling grounds to progress a program like ARQ-234, which holds best-in-class promise for more severe diseases, allowing it to complement the strong position that ZORYVE has already established for us. I'd like to briefly explain the way we think about potential outside innovations in the oil space. When Arcutis first set out its strategy, the goal was to identify, advance, and bring to market top-tier molecules aimed at targets that have already been validated. That approach allows us to build differentiated products more quickly, at lower cost, and with far less risk than alternative methods permit. Slide 20 illustrates that this approach remains in place and continues to guide our business development assessments. Alongside clinically validated targets and distinctive product profiles, we seek opportunities at a point where the clinical and commercial expertise we've accumulated will translate into shareholder value. Perhaps most crucially, we're drawn to opportunities that deliver meaningful innovation against major unmet medical needs within immune-mediated disease. Finally, as Frank has mentioned previously, given the abundance of internal opportunities at our disposal, we view business development as an attractive choice instead of a strategic requirement. Consequently, we will remain disciplined when evaluating business development possibilities and when deciding if we should acquire further assets. At this point I'll hand the call to Latha, who will discuss our 2026 sales outlook along with our capital allocation strategy.

Latha Vairavan executive
#17

Thanks, Patrick. I'm looking at Slide 42. As we laid out when today's call began, the third quarter of 2025 represented another robust period for ZORYVE — favorable conditions created by the launches we have underway, together with demand that kept climbing even in the face of the usual seasonal patterns, produced considerable growth from one quarter to the next. We believe this momentum carries forward through the close of 2025 and on into 2026 and past that. Now that we're starting to move beyond the launch phase for our ZORYVE indications, we expect greater predictability in how fast we grow, which lets us forecast the sales path for upcoming periods with more precision. With that in mind, we're giving sales guidance today for the very first time; for 2026, our expectation is that full year net product revenues land somewhere between $455 million and $470 million. We likewise expect net sales to keep growing strongly during the fourth quarter of 2025, powered by rising patient demand, even though our gross to net rate should show only minor gains relative to the third quarter. Let me shift to how we're allocating capital. As we pointed out earlier today, we expect to reach the significant milestone of cash flow breakeven starting in Q4 of this year. The expense base behind these cash flow projections accounts for the ongoing investment we're making to grow and expand ZORYVE, as we've described today, plus the advancement of ARQ-234; our confidence is high that capital generated by our core ZORYVE business will be sufficient to fund these investments. What makes this possible is a dynamic in which the timing of steadily better cash flow generation from the ZORYVE franchise coincides with rising resource needs. We'll stay protective of shareholder capital and remain attentive in how we manage capital allocation so that this dynamic comes to pass. It's our good fortune to hold a portfolio of high ROI investment opportunities alongside a franchise that generates cash flow, like ZORYVE. I'll turn the call back over to Frank now for some closing remarks.

Todd Watanabe executive
#18

Thanks, Latha. Arcutis has reached a thrilling turning point; through the successful rollout of ZORYVE, we've established a strong base for our company, and we anticipate lasting, meaningful expansion from this franchise. The early wins we've seen with ZORYVE won't just let us put money back into that central operation — they'll also let us fund the pursuit of possible additional indications, which keeps that momentum going and lets us keep developing and pushing forward a pipeline of novel treatments, delivering fresh options to people dealing with immune mediated skin diseases, which is the foundational purpose and driving principle of what we do. With that said, we'll now begin the Q&A portion of the call.

Patrick Burnett executive
#19

I'd say a solid starting point would be simply asking about your own hands-on history with topical corticosteroids across the span of your career — you've witnessed quite a lot shift, and how we think about therapeutics has shifted too. So what has that personal history looked like for you, and could you also touch on how it might have changed throughout that period?

Douglas Diruggiero executive
#20

Okay, so to start, it’s a privilege to be included here. I appreciate the invitation. I entered the field of dermatology 26 years ago, and I’ve remained in it from then on. It was very simple for me to be drawn toward topical corticosteroids as the treatment for everything. And its influence, I’d argue, on how dermatology has developed is likely greater than that of any other product within our specialty. Plus, it has existed for quite a while — 1952 was when it was first formulated into something we could apply to the skin, and it has been in use from that point onward. So my own experience, when I began in 1999, was that topical corticosteroids served as the foundation of treatment — first line, second line, third line, maintenance therapy, every one of those roles. However, we lacked the targeted treatments available today for managing some of these systemic conditions through systemic therapy. As a result, we relied heavily on topical steroids, topical tar, and a number of compounded preparations, along with phototherapy and many of the older conventional systemic drugs. So the landscape has shifted enormously — not only because of targeted systemic treatments, but also due to vehicles, systems for delivering drugs to the skin, and active ingredients that are at last providing steroid-level effectiveness without the adverse effects we have always been aware of — not entirely aware, I should say, but to some degree, perhaps willfully overlooked, and now we simply cannot keep doing that. There is simply too much evidence available, both in what the public knows and in what prescribers know, that we must confront the reality that steroids carry many serious risks. And we cannot pass that risk along — or at least I cannot pass that risk along — to my patients anymore without genuinely having substantial information to provide them. So it becomes a matter of shared decision-making.

Patrick Burnett executive
#21

Yeah. One point in your paper really stuck with me. I believe that through the years, discussion has frequently centered on reactions at the injection site; and many individuals, I think, were relatively at ease with that, particularly in situations where no alternative existed. However, something you bring into sharp relief in your paper is a set of emerging data categories that have appeared, sort of underscoring these effects throughout the body. Is there perhaps a single element of that which hit you hardest? In the paper, I know you addressed diabetes, and you bring up bone fracture along with osteoporosis. Was there any specific one that left a strong impression on you?

Douglas Diruggiero executive
#22

Okay, let me give you two accounts that explain what was behind that, and in doing so I'll get to your question in a roundabout way. There was a patient of mine, a boy aged 13, who came to see me because of eczema — atopic dermatitis — and I prescribed triamcinolone, a mid-potency prescription steroid that gets prescribed extremely often, and this kid also had type 1 diabetes. He'd had it from around age 6. He wore a pump and had a monitor, so he could track his glucose levels carefully. His mother came in — this was roughly 3 years back — and said we could apply triamcinolone to his 2 forearms and then observe his blood sugar climb 40 points within 40 minutes. I was simply stunned by that — that they were able to see such a quick spike in his glucose when a topical steroid cream was applied to roughly 5% to 7% of his body surface area, not the entire body. I started looking into this, asking what the systemic side effects really are. In dermatology our focus is on doing a solid job of protecting patients from cutaneous side effects. If you keep using it too long, and on the wrong parts of the body, it unfolds — it could extend the skin, what we refer to as <<inaudible>>, you might get stretch marks that are strand-like, steroid-induced acne or folliculitis would appear, you get unwanted hair, or hypertrycosis. It could bring about dyschromia, meaning discoloration. I put the question to all these highly experienced derm providers: if a mom wants steroids and she's insisting on getting them, what reasons would you offer her, or to a grown patient, what reason would you give for why they shouldn't receive additional topical steroids? Every one of them listed all of those things. Nobody mentioned anything systemic, because we quickly tie every systemic side effect to the administration of systemic steroids; and we don't — and haven't been — trained to recognize, and do not recognize, the whole body of information showing these medicines get absorbed heavily, and they behave like a systemic drug, the same as taking it by mouth or injecting it. So yes, there's plenty of data out there showing it will raise blood sugar, diabetes, it can produce something known as cushanoid syndrome or adrenal insufficiency; but what surprised me most is the data out there concerning avascular necrosis of the hip. 20 and 30-year olds who've only used topicals, no other systemic case reports, having undergone hip replacements. I pointed to a couple of those during a lecture I gave recently. Osteopritic fractures, I did — spoke about a case report involving an 11-year-old where mid- to high potency corticosteroid creams only, no systemics, just topicals, had been used for 3 years and the child had a wrist fracture and full body osteoporosis resembling that of an 80-year-old, and this kid's 11 and had an osteopretic fracture. What we're observing at this point is a rise in pressure inside the eye; previously, our assumption was that applying steroids just near the eye raised your likelihood of that. What we now understand is that steroid use on any part of the body can raise your risk for glaucoma along with elevated ocular pressure. Therefore, we can no longer ignore the systemic internal effects of a topical steroid applied externally, since it behaves as though we were administering it internally, and we have to confront those realities; this ought to alter how we write prescriptions and how we inform our patients regarding these matters.

Patrick Burnett executive
#23

What feedback are you getting from people in your circle regarding topical corticosteroids' function and the way that might be shifting lately?

Douglas Diruggiero executive
#24

Honestly, it comes as quite a shock when people look at the data, because this isn't something that gets discussed in the clinic — these trials, case reports, meta-analyses, and systematic analyses aren't exactly being promoted or pushed forward. And frankly, in many areas, insurance companies force us to prescribe topical corticosteroids as the first option before we're allowed to move on to the medications we believe are safer and equally effective. So part of it comes down to step therapy requirements, and part of it is simply a knowledge gap. The response I typically get is something like, "I just can't believe it." When I share this information, I do so in a way that's very self-reflective, since for many years I was one of the biggest prescribers of topical corticosteroids in my state. So I'm essentially looking in the mirror asking myself how much I've unknowingly contributed to these problems — but I can't keep contributing to it willingly. I think that's what many others are experiencing too. I've received a lot of amazing feedback, emails, and phone calls from people telling me how this data has affected them and how it's altering the way they treat patients, how they're starting to track the grams of steroids they prescribe, and how they're inquiring about other steroid forms their patients are receiving. These simply aren't things we've been accustomed to slowing down and monitoring — what we termed corticosteroid stewardship — in order to catch up with some of our colleagues abroad or in Canada, where they're starting to monitor these products heavily and provide patient warnings at the point of pharmacy dispensing. Other countries are starting to recognize this and have already become proactive about educating and monitoring these things, and in my view, the U.S. really needs to play a role here. And I believe many of us in dermatology have the capability, and now some momentum, to make it happen.

Patrick Burnett executive
#25

You brought up those sophisticated, targeted topical treatments, ZORYVE being one example. In what way have they factored into this progression and shift throughout your time in practice, considering that topical corticosteroids continue to account for most prescriptions written for individuals dealing with certain chronic inflammatory skin conditions, such as atopic dermatitis, psoriasis and <<inaudible>>?

Douglas Diruggiero executive
#26

During 2025's second quarter—I don't yet have figures for Q3, but Q2 was quite recent—what would you estimate the volume of topical corticosteroid prescriptions written by dermatology offices to be? Only dermatologists, mind you—excluding family medicine and every other field. The largest estimate I've heard someone offer is 500,000 during a single quarter. Typically, people guess somewhere between 200,000 and 300,000, prescribed by the roughly 20,000 dermatology providers practicing today. Then I reveal the actual figure: 2.9 million—not across an entire year, but within just 1 quarter. 2.9 million topical corticosteroid prescriptions dispensed—not merely written—to patients obtaining them from derm providers. Talk about jaws dropping once they grasp how significantly we're fueling this. So even if I could shift just 1% of that—at 1%, that's 29,000—even below 29,000, I'd consider that an enormous impact within a single quarter. These figures genuinely alarm those of us in dermatology once we confront them and understand how greatly we're adding to this issue. Fortunately, we now have outstanding options such as ZORYVE. We'd previously had nonsteroidal topical <<inaudible>> inhibitors, or TCIs—the earliest gained approval during 2000. A better one arrived in 2001, giving us these 2 topical options. The issue was tolerability—it's tough, especially with tacrolimus, which causes stinging and burning, though less so with pimecrolimus—yet they simply don't perform well; their effectiveness was quite unimpressive. Then came a first-generation PDE4 inhibitor—I'd call it an older generation—launched around 2014, '16, and once again: tolerability problems, weak efficacy. Patients want to achieve clear skin, and we want to see them get there. So it was difficult to prescribe pimecrolimus. Now, though, we possess something like ZORYVE—a treatment available to me right now that I can describe as working as effectively as a mid to high potency steroid, based on my experience, with research supporting that claim. It's taken once daily, and you can apply it anywhere. That's what makes a product such as ZORYVE so appealing: no restrictions on duration of patient use. No restrictions on application site. I have been—we have been—part of such a complex care regimen, where you might use this low potency steroid interface, then reach for a mid-potency steroid over here; this one's for your scalp since it's a solution. This is an ointment if the skin is really thick. This particular item comes with a set of instructions — and for these individuals, there are these crane draw pools laid out across all those documented protocols covering red lights and green lights, along with guidance on when it should be used and when it shouldn't. And you ought to witness the comfort that washes over their expression when you tell them, "Here is a single cream you're able to apply wherever you like, whenever you like, it's just one time per day, and it delivers excellent clearance, and it will generate itch data along with strong disease clearance, whether the condition is atopic dermatitis or psoriasis."

Patrick Burnett executive
#27

Given that environment, what would you say is the main obstacle for a number of these more sophisticated targeted topical treatments? What do you view as that obstacle — you have mentioned certain distinctions in the profile between those and steroids, and we — I discussed that previously too — but is it genuinely a matter of profile? Or do other factors also come into play in this shift you are describing?

Douglas Diruggiero executive
#28

Okay, so I brought this up before — it's about step-through therapies. The biggest obstacle we face is insurance plans that make us prescribe things we'd rather not put first, or force us to try them, or they make approval incredibly hard to obtain. So honestly, when a rep walks in, the question isn't whether you'll give us a trial or let us try the medicine. What they truly need to say — for practically every drug these days — is: will you go to bat for us? Simply trying it is one thing. Trying it just means a denial is coming, and after that you fall right back into your generic prescribing routine. But that rep has to step up somewhat and advocate for a product you know is safer and effective. That's the only way these insurance companies will be persuaded that demand exists. Convincing patients about safety, I believe, is simple. Giving them samples or getting them started on something and letting them watch it work is simple too. So the 2 primary categories — safety always sits in the driver's seat, and whatever relates to efficacy or effectiveness rides shotgun. Those are the 2 things up front: you want safety, and you want it to work. Then in the back seat of any car: is it convenient? Can you get it filled? Will the patient stay compliant? When you've got something once a day, compliance runs high. You've got something that doesn't burn or <<inaudible>> compliance runs high. You've got something that works — compliance runs high. What causes non-compliance is often an insurance company trusting us to do what we believe is best for our patient, and I'd say that's among the bigger blocks. I will say improvements are happening — I have far more patients walking in thanks to TikTok. I know we tend to throw TikTok and Google, Dr. Google, under the bus quite a bit, but in some ways it's been really helpful. And when it comes to educating patients about corticosteroid withdrawal and every danger associated with it, many patients come in and they are — they sit there and ask me: what is this steroid stairway you're prescribing me, because I don't want my child on a steroid. Now they're saying preemptively, "I don't want to be on a topical steroid." So over the last 2 years especially, I've witnessed a shift, as more and more patients — regardless of their insurance, regardless of their economic status — are themselves starting to say, "I don't want to be on this." And I'm in World Georgia. It's not as if we're dealing with a place where lots of flute-like symptoms show up, which is where you'd figure that would occur. I practice in a really rural setting, and weekly I still get patients asking me whether something is a stronger steroid, because they refuse to take that. Their pediatricians have already given it a shot. They don't want it in their record. They don't want to take it. A man came to see me recently, and the discussion was about dermatitis — he's 40 years old, and he's had it from the moment he was born. He told me that if I were to hand him a prescription for that, he would never come back again. That was his very first appointment with me. My reaction was, all right then. I told him I had no intention of doing so, but it was useful information, and I needed to persuade him, and he said his wife forces him to come in once every 2 years to check whether anything new has come out. He wanted me to explain his condition and lay out his choices. So we are witnessing a change; perhaps it isn't moving as quickly as we'd like, yet it is taking place. It is taking place.

Executive executive
#29

Thanks, Frank. Sadly, Todd isn’t feeling well today, so he won’t be with us for the Q&A portion, but Frank, Latha, and Patrick are here with me. <<operator_script>>. Let’s get started right away. The first question is for the group regarding topical steroid conversion. During the call, you mentioned how the treatment paradigm is evolving, with nonsteroidal topicals beginning to replace topical corticosteroids. What steps are you currently taking, or what steps do you intend to take, to speed up that shift?

Brian Scholkoff executive
#30

This strikes me as an extremely important thing to ask about, given how much rides on this for ZORYVE going forward. I also think it's worth really emphasizing that the shift we're seeing toward topical stewardship — meaning doctors becoming more careful and sparing when they prescribe topical steroids, using them only for very brief periods — is something developing inside dermatology, and it's the dermatology clinicians who are genuinely driving it. Patrick and Douglas both spoke about this earlier on today's call, and the evidence keeps accumulating that using topical corticosteroids over a long stretch produces severe negative consequences, affecting patients both at the site of application and throughout the body — those adverse reactions — and as Doug mentioned, dermatology clinicians are becoming aware of this information, they're talking it over with one another, and they're changing how they treat patients. I attended the fall clinical conference over the weekend, and from the podium there was quite a bit of talk about this; Patrick brought up the SDNP and the SDPA statement. So this is happening on its own, and the whole nonsteroid topical category will gain from it; but in particular, it benefits us because our share of that nonsteroidal market is very strong. As for what Arcutis itself will do to accelerate that shift, there are essentially 3 levers to think about. The first one, I'd say, is the sales force. Number two concerns getting the drug to patients, while number three involves what we're doing on the promotional side; when it comes to our sales team and patient access, our position is already quite favorable. Roughly 40 representatives joined us during the past year to support the atopic dermatitis rollout. That gives us a robust field force reaching the dermatology practitioners responsible for roughly 90% of all topical scripts written in that specialty. Turning to access, as I believe most people are aware, our coverage is quite solid among both commercial and Medicaid members, and efforts are underway to broaden the Medicaid footprint even more, plus we're hopeful about beginning to secure Medicare reimbursement too. From a coverage perspective, I'd say we're sitting in a pretty solid spot. And last, when it comes to marketing — once again, my sense is that our position there is quite strong. As an organization, we've taken a deliberate approach to what we put into marketing, since allocating capital requires care on our part, and beyond that, we've also been getting a lift from that organic movement I brought up earlier, which is building from the ground up within dermatology. So my thinking is that once ZORYVE, the franchise, begins producing cash, as Latha noted, this is likely one of those places where we'll put some additional dollars into what we spend on marketing.

Executive executive
#31

Alright, thanks. Moving on to the next question, which concerns what was said about peak sales. The ask is this: within your peak sales guidance, you stated that a 15% to 20% share of the topical corticosteroid market is achievable. What makes you confident that you can expand from the roughly 3% share you hold today up to that range? Also, any thoughts on the timeline for that process and for capturing that share?

Brian Scholkoff executive
#32

Okay, given that Todd is unwell today, you'll be hearing quite a bit from me. But the strongest sign that this shift is underway and will keep going, I believe, is how quickly nonsteroidal topicals are already capturing share from topical corticosteroids. As we discussed earlier on this call, the non-steroidal category is expanding at a very fast clip, even though it starts from a small base — yet when you factor in that the nonsteroidal market grew about 50% in just the past 12 months alone, correct? So the growth trend is extremely powerful, and ZORYVE is responsible for driving a large portion of it. It's worth keeping in mind that although this robust growth trend in steroid conversion and this dialogue around topical steroid stewardship is happening, it's only a very recent development. Consider that the led wall paper only appeared in January of this year, and the SDNP and SDPA statements only arrived a few months back. So these discussions are occurring at this moment, and a year ago they simply weren't taking place nearly as often. So I believe we are truly only at the outset of witnessing how this shift in dermatologists' thinking will play out. Regarding what specifically will drive ZORYVE's market share going forward, once again, the most significant driver, in my view, is the heightened emphasis on topical steroid stewardship that we just covered, and that will depend on — it will require a far greater dependence on nonsteroidal topicals such as ZORYVE. And once more, we are positioned to benefit disproportionately from that shift because of our <<inaudible>> share of the non steroidal class and our expanding share of the non-steroidal classes we've already discussed. A second lever, I believe, is our growth into new treatment settings as we keep building awareness and adoption in primary care and pediatrics through our Cola partnership. Third, the additional data generation that Patrick described today, I think, will drive prescriber behavior for particular key populations, such as patients with nail psoriasis or palmoplantar psoriasis, which fall within our current indication, but we still lack very much data on that. So that will be a valuable incremental data set. On the access side, our reimbursement position is excellent, but there are further opportunities ahead regarding broadening our Medicaid coverage and also securing Medicare coverage. And finally, the actions we take that truly spotlight or fuel patient awareness to reinforce the trends already visible, where patients arrive and request from their doctors something that isn't a steroid, correct? There is a substantial public conversation surrounding this subject. And I believe that will serve as another key driver for <<inaudible>> future growth. When it comes to timing, again, if you consider the analogs Patrick mentioned before, these kinds of shifts in how treatment is practiced do require time to take effect. I think the pace of adoption we're already seeing has us quite encouraged; and I think the demand growth you observed this quarter serves as a solid data point demonstrating that this is taking place. But moving away from those older topical steroids toward the more recent advanced topical therapies is going to require some time. Looking at the analogs, somewhere between 5 and 10 years for that to occur, and with the topical steroids we're still quite early in that process; so I think it's difficult to predict, but it won't happen overnight, but I think we're quite confident it will occur for every one of the right clinical reasons, and we're already beginning to see these trends unfold.

Executive executive
#33

All right. Great. Now let's turn our attention to ARQ-234. A number of inquiries have come our way about this, and quite a few simply point to clinical data already available that lowers the risk for the class or the target; however, one question is more pointed, concerning ARQ-234 itself. After halting its Phase II study in atopic dermatitis, Eli Lilly chose to discontinue its CD200R agonist for strategic reasons. Is there anything you've learned from that effort that could be brought over to 234, or any remarks you might offer about how the 2 programs differ?

Todd Watanabe executive
#34

Yes. So Patrick, do you want to take that one?

Patrick Burnett executive
#35

Absolutely. Thanks, Frank. Right. We've been monitoring the OLE program extremely carefully. I mentioned this briefly during the presentation. One of the main reasons we feel confident proceeding with ARQ-234 comes down to the structure itself. The Lilly molecule was a monoclonal antibody binding outside the native binding site, while ours is a fusion protein designed for extended half-life and featuring 2 high-affinity modified CD200 ligand; so truly a distinct molecular strategy. We also have preclinical data indicating we achieve greater affinity. That gives us strong confidence, along with this extended PK half-life that we believe may offer advantages regarding how frequently we dose. Naturally, that needs confirmation in the trial we intend to launch at the start of 2026. So we've tracked that program quite attentively. And once again, frequently it also boils down to how well a study is executed, and we've run numerous trials in atopic dermatitis; I believe our clinical development and clinical operations teams are outstanding. So I think that will additionally assist us in gaining a very clear picture. The GWAS data and the sort of early evidence that drew Lilly toward atopic dermatitis still holds; we find that quite persuasive. And we believe ARQ-234 is the correct molecule and atopic dermatitis is the correct condition for us to pursue further. So we're eager to get that kickoff.

Executive executive
#36

All right. Now, regarding what's happening with LCM. When it comes to vitiligo and HS, the thing being asked is this: while you're running studies of ZORYVE for vitiligo and HS, what's your thinking on how competition will play out with other medications already cleared or still being worked on for those same conditions? And tied to that, a follow-up: could you elaborate on how the trials are designed — for instance, how large they are, whether there's a control arm, and how long they run?

Todd Watanabe executive
#37

Sure. Yes. Patrick, I think that's probably the best handled by you again.

Patrick Burnett executive
#38

All right, that makes sense. Yes. So when we consider how we manage the lifecycle and the competition involving HS and vitiligo, I believe the ideal starting point is to examine those indications where approval already exists and where we already face rivals in the form of topical corticosteroids and branded topicals. In that setting, which aspects of our profile have driven such strong results? It essentially boils down to efficacy, safety, tolerability, once-daily use, ease of administration, the ability to apply pretty much anywhere on the body, plus our commercial execution and our access. That gives us considerable confidence in our clinical development, in our commercial execution, and in our capacity to apply these strengths to both of these new indications. Now, focusing specifically on vitiligo, in my view once-daily dosing will matter enormously for patients with this disease. People with vitiligo must treat for an extended period, usually months, before any benefit begins to appear with essentially any therapy; therefore, being able to do that only one time per day will — it generally delivers better compliance than dosing every day. For that same reason, how quickly repigmentation occurs is another important possible point of differentiation. So that is something we will examine very carefully as we run this next study, and we will need to see those results once they reach the clinic. So shifting to hidradenitis suppurativa. In this case, there is substantial white space for a topical therapeutic aimed at inflammation. At present, treatment consists mainly of topical antibiotics, after which patients jump straight to a systemic therapy. So having an effective topical option usable in earlier-stage patients as monotherapy, and in later-stage patients as an adjunctive treatment that complements their systemic therapy, represents a very, very strong profile. That mirrors what we have observed in atopic dermatitis and psoriasis. Indeed, systemic therapies for hidradenitis suppurativa leave considerable room for adjunctive treatment that can genuinely help patients reach their target treatment; so we are highly optimistic about how this profile fits with both of those indications.

Executive executive
#39

All right, great. Let's take the next question now, which centers on what we reported in quarter 3 — more precisely, net sales. The ask is this: could you walk us through how we get from a 13% rise in total prescription demand on a sequential basis to a 22% increase in revenue, also sequentially, for that quarter?

Todd Watanabe executive
#40

Absolutely, and thanks for raising that. The main factor behind the portion of our product revenue growth that isn't tied to volume would be gains in gross to net. During the quarter, what we observed was this: when a patient hasn't yet met their deductible for the year, we bring their cost down to either $0 or $35. That means Arcutis has to absorb the extra amount tied to their deductible until they hit their yearly deductibles. In Q3, what we found was that patients moved through their annual deductibles, likely faster than we had anticipated. As a result, usage of our co-pay program has come down, and that feeds straight into higher revenue for each prescription, and it occurred sooner than we'd expected; however, that likely also suggests there may be less room for improvement on that piece in Q4 compared with what Q3 showed. So our expectation is that GTN stays quite steady, likely from Q3 into Q4; and it's worth stressing that every other element that could add to non-demand revenue growth was not meaningful during this period; so demand growth plus the gross-to-net improvement are really what's fueling this outperformance.

Executive executive
#41

Alright. Great. Now, moving on, our next question concerns business development and innovation from outside sources. The question says that Frank brought up looking externally for innovation. Could you go into more detail about the development stage, what kinds of assets in terms of modality, and then the therapeutic areas you have interest in — in particular, are you seeking things that are closer to ZORYVE, or further away from ZORYVE when it comes to diversifying?

Todd Watanabe executive
#42

Absolutely, of course. Patrick is heading up all of this work, so I believe I'll turn that question over to Patrick.

Patrick Burnett executive
#43

Yeah. So, when you take a look at what we've got in development, ARQ-234 is about to go into the clinic, and we haven't spent much time discussing the chances to extend the ZORYVE life cycle. So in a perfect world, what we'd want is something sitting somewhere between those two. That said, I'd say we're quite opportunistic, and the thing that matters most is locating an asset we have a lot of confidence in and feel genuinely enthusiastic about, one that addresses an unmet need. Once again, dermatology comes first for us, since we believe that's where our expertise lines up best. That said, because of how much knowledge the team has and the experience we bring from beyond dermatology, we aren't confining ourselves to that area; we're genuinely examining inflammation and nearby spaces for assets that would slot in nicely with what we're developing. So really — as I said during the discussion — the thing we're after is the right asset, and we don't feel any pressure to bring one in simply because of the current state of our pipeline. That's because we're confident about advancing 234 and about everything the ZORYVE life cycle management offers us.

Executive executive
#44

All right, that's helpful. And if we could just remain on 234 briefly, someone submitted a question here. In Alzheimer's disease patients, would the target for ARQ-234 overlap with the ZORYVE target population for that particular indication? Or what's the right way for us to consider that?

Todd Watanabe executive
#45

Yes, Patrick, that's probably back to you again.

Patrick Burnett executive
#46

Right, and our approved atopic dermatitis indication covers patients starting at age 6, in the mild-to-moderate range, whereas when you develop systemics and biologics — especially the latter — the focus tends to be on moderate-to-severe disease. So those two areas do overlap somewhat. But the key point, I'd say, is that one benefit of the ZORYVE profile is that its label and its safety profile don't rule it out for use alongside systemic therapy, and that's something we've heard from many of our customers — they've found it useful. And frequently, a patient sitting in that moderate-to-severe zone will shift down into more of a mild-to-moderate category, where, while on a biologic or systemic, ZORYVE would be appropriate to use. So we don't view them as necessarily competing, just as we don't view ourselves as competing with systemic treatments — instead, they complement one another in terms of being able to keep a patient going with this chronic disease over their whole lifetime, without having them turn to topical corticosteroids.

Executive executive
#47

All right. Great. Now the following question returns to the subject of BD, and I believe we touched on it somewhat, yet because of the position you hold in dermatology offices, might you think about bringing in a biologic aimed at a new dermatology target to develop, or might you likewise think about partnering on one that is already in development for U.S. rights, simply to more precisely calibrate what we are examining there.

Todd Watanabe executive
#48

Essentially, there were two pieces to that, correct? If I recall, the first part asked whether we'd think about using a biologic for AD. And the second part was about whether we'd look at partnering on something already at the commercial stage.

Executive executive
#49

Correct.

Todd Watanabe executive
#50

Yeah. So, regarding that first item, we would definitely look at bringing a biologic into this area through a partnership, and that essentially sums up what Patrick was saying. When it comes to treatment modality at Arcutis, we truly have no preference. That means an oral, an injectable, or a topical—any of those are things we can pursue; so across our business development work, we're assessing that entire landscape. As for teaming up on a product that has already reached commercial stage and is on the market, I wouldn't rule it out, though it likely isn't our top priority; here at Arcutis we've assembled a remarkably robust development group spanning clinical and manufacturing. Consider 9 successful Phase IIIs and 6 FDA approvals, and I believe this team has repeatedly demonstrated its capacity to carry out development programs and generate shareholder value; a piece of how we think about business development involves continuing to draw on this genuinely very powerful development engine we've created; being at commercial stage is more about drawing on the commercial organization we possess, yet that commercial organization is quite occupied with launching all these different indications for ZORYVE. So I'd say that is likely a lesser priority for us when it comes to business development and commercial stage products.

Executive executive
#51

All right, that makes sense. Moving on to another question, still related to BD, and this one focuses more on how we view possible limits around size. So would there be any cap on size that we'd take into account? And then based on the size, would there be varying factors, ranging from financing strategy to backing that?

Todd Watanabe executive
#52

Okay, given how the stock has done today, the figure is likely somewhat larger — but Latha, would you like to handle that question?

Latha Vairavan executive
#53

Certainly. So I'd say — what drives us primarily where the balance sheet is concerned is how ZORYVE's trajectory develops, and we will, as I mentioned, keep our sights on the milestone of reaching cash flow breakeven during Q4 of this year. Beyond that, there's a sharper emphasis on growing and expanding, just as Frank laid out today, and on providing funding for those efforts; after that, when you consider innovative BD, we enjoy a fair amount of flexibility through our debt facility with SLR, and likewise, contingent on the asset and the quantum, and as Frank noted, given where the stock price stands today, we'll evaluate which funding mechanisms best suit our capital strategy and how to deploy them for BD.

Executive executive
#54

All right, that's good. The following question returns to the subject of ZORYVE's life cycle management. This one has 2 parts. First, among the various indications we presented earlier, how are we approaching the question of prioritization? What sort of framework guides our choice of where to go next? Second, how do you expect that adding new indications could help your commercial work across psoriasis, sebderm, and atopic dermatitis?

Todd Watanabe executive
#55

Sure. Perhaps I'll handle the latter portion of what you asked, and then, Patrick, I'll hand things over so you can discuss the first part. When you consider truly displacing topical steroids as the standard topical treatment within dermatology — the greater the number of chances a physician gets to prescribe our product, the more it transforms into a routine; it becomes the treatment they reach for automatically, correct? That's evident in the figures we shared previously regarding what occurs as a physician moves from prescribing ZORYVE for 1 condition to 2 conditions to 3 conditions, correct? The growth isn't linear — it climbs exponentially. Going from 1 to 2 represents a threefold jump. Moving from 2 to 3, or 1 to 3, amounts to a tenfold rise in prescribing. We'd anticipate a comparable pattern when they are using — when they're able to use ZORYVE for virtually every patient who comes through their office door. So I believe a synergistic impact will occur alongside our current indications as physicians prescribe ZORYVE progressively more often. And something we've genuinely observed, especially regarding access, I'd say, is that the more physicians prescribe ZORYVE, the more they prescribe ZORYVE, correct? Since they recognize how efficacious it is, how well tolerated it is, and most crucially, I believe, how simple it is to obtain for their patients — confidence builds alongside familiarity. And with indications expanding, we ought to witness something quite comparable there, on top of the growth stemming from the new indication itself. Then, Patrick, would you perhaps tackle the prioritization question?

Patrick Burnett executive
#56

Sure, of course. So when we're figuring out where to focus first, we're beginning with HS and vitiligo. However, those two aren't the full scope of the indications we're examining, and we laid out that wide-ranging list. And I believe that's among the essential pieces when it comes to substituting for steroids, since you can't substitute for steroids if they're effective across a great many indications while your therapy only helps with 1 or 2. So I'd say that's a genuinely vital element of our effort to replace topical corticosteroids. When we consider how to rank those, the real question is: what clinical profile are we observing? What efficacy and safety are we observing, and that's going to emerge from both — the studies we're running and the reports arriving from the field. And daily, we're learning more and more about those, and that informs our sense of how great the unmet need is. And what sort of profile and efficacy we think we'll be able to observe. And then we pair that with the commercial assessment, so we can genuinely grasp how that profile fits; and I mentioned that briefly with the first question we took regarding life cycle management — what do we want to see in vitiligo, what do we want to see in HS. And that's really about trying to incorporate that commercial assessment to ensure we're developing in an indication where a market will exist once we reach the other side. But we know for both HS and vitiligo that these are quite favorable. We'll carry out the same sort of activity as we look toward new indications past those.

Executive executive
#57

Alright, let's shift focus to the latest introduction of ZORYVE Foam 0.3, along with scalp and body involvement in plaque psoriasis. During quarter 3, the cream 0.3% showed somewhat softer expansion relative to the foam. Does that stem from plaque psoriasis patients moving over to foam instead of cream? Or what's your read on how things will unfold between these 2 products?

Todd Watanabe executive
#58

Yeah, this question has come up several times before. And my view is that it's highly improbable a patient doing well on the cream would make the change to the foam. I've definitely heard about patients holding prescriptions for the two products, and there's nothing stopping that from happening — suppose you had a plaque on your elbow and another on your scalp; perhaps the doctor writes for both, even though the foam can be applied to the body and performs identically to the cream. I believe we keep seeing NRx growth for the cream. So I don't believe this cannibalization question really applies to us. I don't believe any cannibalization is happening, since the cream continues to grow. What I suspect is actually happening is that among new patients who have not yet tried ZORYVE, a larger share now — psoriasis patients in particular — are receiving the foam, and some of those may be people who in the past would have been given the cream. Another point worth stressing, and I've made it before, is that from a shareholder perspective, which SKU a patient receives truly doesn't matter, provided they're getting ZORYVE, correct? COGS is basically identical across the products. Pricing is identical. Access looks very similar. So provided total ZORYVE volume keeps expanding, shareholders gain from that expansion. And I think with both the cream and the foam available as options in psoriasis, plus 2 distinct presentations for atopic dermatitis now tailored to those patients, and the foam for seb derm, we're simply handing doctors more and more chances to prescribe ZORYVE for treating patients who have inflammatory skin diseases.

Executive executive
#59

Alright. We’ve likely got room for only one additional question now, and that last question concerns the incremental data generation opportunities Patrick mentioned earlier in the presentation. The question is this: for the data generation opportunities in your current indications, the patient figures shown on the slide, are those incremental new patients who will be covered and add to the market opportunity? Or how should we think about that?

Todd Watanabe executive
#60

Yeah. That's another excellent question. When we talk about generating incremental data, those patients actually already fall within our serviceable obtainable market. Take nail psoriasis as an illustration: we mentioned 3 million to 5 million psoriasis patients dealing with nail crisis. That group sits inside the psoriasis market we already target and discussed. What we do anticipate, though, is that this will produce disproportionately higher uptake among these subpopulations, especially the truly difficult ones — nail psoriasis ranks among the hardest conditions to treat. Even when a biologic is used, it frequently fails to clear it, and palmoplantar psoriasis, another plaque psoriasis form, is likewise often very challenging to treat. So if we're able to generate very strong data on how efficacious ZORYVE is in those hard-to-treat patient populations, you'd expect to see even stronger adoption of ZORYVE within those patient subsets; that's exactly why we consider this incremental data generation so important. And Patrick, I'm not sure whether you have any additional thoughts you'd like to add there?

Patrick Burnett executive
#61

Absolutely, I'm with you on that. When someone arrives with psoriasis, the nails get examined every time—for each person with psoriasis, both the nails and elbows are inspected. Once you've observed nail psoriasis, your immediate thought is that ZORYVE will help in that case, unlike any other topical treatment, and perhaps you won't need to put them on a systemic therapy. To me, that's a massive benefit we have, and it genuinely shifts how someone views the profile, making it seem even better. So I fully back your point, Frank.

Executive executive
#62

All right, that brings us to the part where we take your questions. Once more, we want to express our appreciation to everyone for fitting us into your crowded calendars today and being here with us at this Investor Day.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Arcutis Biotherapeutics, Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.

Get an API key View API docs →

For developers and AI pipelines

Programmatic access to Arcutis Biotherapeutics, Inc. earnings transcripts and 132,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $162 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.